CHMP meeting highlights: April 2024
European Pharmaceutical Review
APRIL 30, 2024
Last week, the US FDA approved a new gene therapy for eligible adults with haemophilia B. If approved, fruquintinib could provide a new oral, chemotherapy-free option as the first and only selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR) receptors approved in the EU for this disease, according to Takeda.
91 
Let's personalize your content